The Tolerability Contrast

Petrelintide

Also known as ZP8396

Summary coverage

At a glance

What it is: Long-acting amylin analogue with a ten-day half-life and a mild GI profile.

Evidence: Clinical trialsHow the tiers workTwo Phase 1 trials published in Diabetes, Obesity and Metabolism in July 2026: a single-ascending-dose study across 0.04–2.4 mg subcutaneously plus a 0.35 mg intravenous dose, and a multiple-ascending-dose study of six weekly doses at 0.6 and 1.2 mg and 16 weekly doses escalated every two weeks to 2.4, 4.8 and 9.0 mg. Why this tier

Half-life: Approximately 10 days
Routes: Subcutaneous, Intravenous
Category: Metabolic
FDA: Investigational; As of 3 August 2026. What that means
WADA: We do not state a status

Putting Petrelintide on a schedule, with the vial it comes from and a log of each dose, happens in the app: Claritide for iPhone.

Evidence

Why this tier

Two Phase 1 trials published in Diabetes, Obesity and Metabolism in July 2026: a single-ascending-dose study across 0.04–2.4 mg subcutaneously plus a 0.35 mg intravenous dose, and a multiple-ascending-dose study of six weekly doses at 0.6 and 1.2 mg and 16 weekly doses escalated every two weeks to 2.4, 4.8 and 9.0 mg. Half-life approximately 10 days; weight reduced by up to 8.6% after 16 weeks. Nausea 16.7–33.3% against 16.7% on placebo, diarrhoea rare, vomiting only in the single participant who discontinued, and no serious or severe treatment-emergent adverse events. Phase 1 evidence is about safety and dose-finding, not efficacy.

Overview

What it is

Petrelintide is a long-acting amylin analogue from Zealand Pharma with two published Phase 1 trials. Its interest is the tolerability contrast: nausea rates barely above placebo in the multiple-ascending-dose study, with vomiting confined to the single participant who discontinued, a different profile from the gastrointestinal burden that defines the GLP-1 class.

Mechanism

How it works

Petrelintide is an amylin receptor agonist engineered for a long half-life, around ten days, so it supports weekly dosing with relatively flat exposure. Amylin signalling produces meal termination, slower gastric emptying and post-meal glucagon suppression, which is a distinct appetite pathway from GLP-1.

Dosing

Commonly researched ranges

These are figures reported in published literature and practitioner protocols: a commonly researched range, not a recommendation. Claritide does not tell you what to take.

Phase 1b multiple ascending dose · the target doses0.6–9 mg
Weekly, escalated every two weeks over 16 weeks in the longer cohort
Six weekly doses of 0.6 and 1.2 mg in one arm; 16 weekly doses escalated every two weeks to target doses of 2.4, 4.8 and 9.0 mg in the other. Those three are the only weekly doses this compound has been maintained on. Stated first because the row below it is a dose-ranging procedure rather than a regimen. Note that several summaries attribute 2.4 / 4.8 / 9.0 mg to the Phase 2 ZUPREME-1 trial. They are Phase 1b figures, and the Phase 2 doses are sponsor-blinded and unpublished.
Phase 1 single ascending dose0.04–2.4 mg
Single subcutaneous dose
Plus a 0.35 mg intravenous dose. Phase 1 dose-ranging, not a regimen: the 0.04 mg figure is where a first-in-human study starts, not an amount anyone was treated with.

Phase	Amount	Frequency	Timing	Note
Phase 1b multiple ascending dose · the target doses	0.6–9 mg	Weekly, escalated every two weeks over 16 weeks in the longer cohort	Not established in available literature	Six weekly doses of 0.6 and 1.2 mg in one arm; 16 weekly doses escalated every two weeks to target doses of 2.4, 4.8 and 9.0 mg in the other. Those three are the only weekly doses this compound has been maintained on. Stated first because the row below it is a dose-ranging procedure rather than a regimen. Note that several summaries attribute 2.4 / 4.8 / 9.0 mg to the Phase 2 ZUPREME-1 trial. They are Phase 1b figures, and the Phase 2 doses are sponsor-blinded and unpublished.
Phase 1 single ascending dose	0.04–2.4 mg	Single subcutaneous dose	Not established in available literature	Plus a 0.35 mg intravenous dose. Phase 1 dose-ranging, not a regimen: the 0.04 mg figure is where a first-in-human study starts, not an amount anyone was treated with.

Cycle guidance: Not established in available literature
Goals: Fat loss

Legal standing

Where this sits with the FDA

Dated, sourced, and separate from whether it works. Removal from a warning list is not permission to compound.

Investigationalas of 3 August 2026 · US

In early clinical development with no approval anywhere and no compounding pathway.

Primary source

Sport

WADA status

The 2026 Prohibited List entered force on 1 January 2026.

We do not state a status

Not named on the 2026 Prohibited List. We could not determine a classification and do not state one.

We looked and could not resolve it. This is not the same as "not prohibited". Treat it as unresolved and check with your federation before competing.

Reconstitution

Mixing recipes our sources document

Concentration (mg/mL) = vial mg ÷ diluent mL. On a U-100 barrel, 1 unit = 0.01 mL.

Not established in available literature. Use the calculator with the figures printed on your own vial.
Open the calculator

Expectations

Week by week

What our material describes people reporting. Individual responses vary widely.

Not established in available literature.

Tolerability

Side effects

Grouped by how often our sources report them. Percentages appear only where a published trial figure exists.

Common

Nausea16.7–33.3% across arms against 16.7% on placebo. The low end is level with placebo, which is unusual in this class.

Rare

VomitingOccurred only in the single participant who discontinued.

Safety

Contraindications and interactions

Do not use if

Not established in available literature.

Interactions

Not established in available literature.

Absence from this list does NOT mean safety. It means lack of research.

Handling

Storage and cost

Storage: Our sources publish no reconstitution or storage protocol for petrelintide.
Cost: Not established in available literature

Deep dive

Petrelintide in full

Limited coverage

Petrelintide (ZP8396) is a long-acting amylin analogue from Zealand Pharma, with a half-life of about ten days.

The Phase 1 data

Two trials published in Diabetes, Obesity and Metabolism in July 2026. Single ascending dose: 0.04 to 2.4 mg subcutaneously plus a 0.35 mg intravenous dose. Multiple ascending dose: six weekly doses of 0.6 and 1.2 mg in one cohort, and 16 weekly doses escalated every two weeks to 2.4, 4.8 and 9.0 mg in another.

Weight reduced by up to 8.6% after 16 weeks.

Why it earns a record

The tolerability numbers. Nausea 16.7 to 33.3% against 16.7% on placebo. The low end is level with placebo. Diarrhoea rare. Vomiting occurred only in the single participant who discontinued. No serious or severe treatment-emergent adverse events.

Set that against the GLP-1 class, where gastrointestinal effects are the dominant reason people stop, and where survodutide's Phase 3 reported GI adverse events in 89.7% of the high-dose arm.

That contrast is useful for calibrating what "GLP-1 side effects" actually are: not an unavoidable cost of losing weight pharmacologically, but a property of that particular receptor.

One caution on reading this. Phase 1 is a safety and dose-finding exercise, usually in small, healthy, carefully selected groups. The 8.6% figure is not a Phase 3 efficacy result and should not be lined up next to one.

References

Sources

1
Diabetes, Obesity and Metabolism, July 2026 · two Phase 1 trials of petrelintide
PMID 42017294 Source
2
Zealand Pharma · Phase 1b multiple-ascending-dose presentation, 20 June 2024. The 2.4 / 4.8 / 9.0 mg target doses (dose review, 2026-08-17)
Source
3
NCT06662539 · ZUPREME-1 Phase 2, whose arms are labelled "Dose 1" to "Dose 5" with no milligram values published (dose review, 2026-08-17)
Source

Every record in this library is free to read, and it stays free. Your own schedule, vials and log live in the app: Claritide for iPhone.